Therapeutic effects of direct renin inhibitor aliskiren on ambulatory blood pressure profile in essential hypertensives

Therapeutic effects of direct renin inhibitor aliskiren on ambulatory blood pressure profile in essential hypertensives - Therapeutic effects of direct renin inhibitor aliskiren on ambulatory blood pressure profile in essential hypertensives

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003936

Enrollment

Registered

2010-07-21

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Essential hypertensives

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Essential hypertensives who are untreated more than 1 month. 2. Office systolic blood pressure >= 140 mmHg and <180 mmHg, or office diastolic blood pressure >= 90 mmHg and < 110 mmHg. 3. Informed consent is obtained.

Exclusion criteria

Exclusion criteria: 1. Office systolic blood pressure >= 180 mmHg, or office diastolic blood pressure >= 110 mmHg. 2. Heart disease, cerebrovascular disease, or ckronic kidney disease with urinary protein excretion >= 300 mg/g-cr or estimated GFR < 60 ml/min/1.73 m2. 3. Cyclosporin treatment. 4. History of hypersensitivity of aliskiren. 5. Pregnant women or women suspect of being pregnant. 6. Arrhythmia. 7. Secondary hypertension. 8. Patients ineligible for the study determined by doctors

Design outcomes

Primary

Measure	Time frame
1) Office blood pressure: -2, 0, 4, 8, and 12 wks. 2) Ambulatory blood pressure profile, aortic blood pressure (non-invasive central blood pressure), baPWV: 0 and 12 wks. 3) Urinalysis and blood analysis: Urine; protein, albumin, creatinine. Blood; complete blood count, total protein, albumin, blood urea nitrogen, creatinine, uric acid, electrolyte, AST, ALT, ALP, LDH, CK, T-bil, fasting blood glucose, IRI, HOMA-IR, HbA1c, T-cho, LDL-cho, HDL-cho, TG, high-sensitivity CRP, BNP, plasma renin activity, aldosterone concentration. 4) Adverse events: 4, 8, and 12 wks.	—

Measure

Time frame

1) Office blood pressure: -2, 0, 4, 8, and 12 wks. 2) Ambulatory blood pressure profile, aortic blood pressure (non-invasive central blood pressure), baPWV: 0 and 12 wks. 3) Urinalysis and blood analysis: Urine; protein, albumin, creatinine. Blood; complete blood count, total protein, albumin, blood urea nitrogen, creatinine, uric acid, electrolyte, AST, ALT, ALP, LDH, CK, T-bil, fasting blood glucose, IRI, HOMA-IR, HbA1c, T-cho, LDL-cho, HDL-cho, TG, high-sensitivity CRP, BNP, plasma renin activity, aldosterone concentration. 4) Adverse events: 4, 8, and 12 wks.

—

Countries

Japan

Contacts

Public ContactKouichi Tamura

Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine

tamukou@med.yokohama-cu.ac.jp045-787-2635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026